• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.

作者信息

Sung Wen-Wei

机构信息

Department of Urology, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

出版信息

Eur Urol Oncol. 2024 Feb;7(1):163. doi: 10.1016/j.euo.2023.08.007. Epub 2023 Sep 9.

DOI:10.1016/j.euo.2023.08.007
PMID:37679244
Abstract
摘要

相似文献

1
Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.回复：沈伟、伊恩·M·麦克尔里、法昆多·达瓦罗等人。序贯膀胱内注射吉西他滨和多西他赛是卡介苗治疗中危非肌层浸润性膀胱癌的替代方案。《欧洲泌尿外科肿瘤学杂志》。2023年；6：531 - 534。
Eur Urol Oncol. 2024 Feb;7(1):163. doi: 10.1016/j.euo.2023.08.007. Epub 2023 Sep 9.
2
Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.回复：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等。卡介苗或早期根治性膀胱切除术治疗欧洲泌尿外科学会极高危非肌层浸润性膀胱癌患者的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。
Eur Urol Oncol. 2024 Apr;7(2):300. doi: 10.1016/j.euo.2023.09.016. Epub 2023 Oct 12.
3
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.序贯膀胱内吉西他滨和多西他赛是卡介苗治疗中危非肌肉浸润性膀胱癌的替代方案。
Eur Urol Oncol. 2023 Oct;6(5):531-534. doi: 10.1016/j.euo.2023.06.011. Epub 2023 Jul 18.
4
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).背景和 ECOG-ACRIN EA8212 更新：一项随机 3 期试验，比较卡介苗（BCG）与多西他赛和吉西他滨膀胱内治疗在 BCG 初治高级别非肌肉浸润性膀胱癌（BRIDGE）中的作用。
Eur Urol Focus. 2023 Jul;9(4):561-563. doi: 10.1016/j.euf.2023.06.006. Epub 2023 Jul 6.
5
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.序贯膀胱内注射吉西他滨-多西他赛与卡介苗（BCG）治疗非肌层浸润性膀胱癌的初步成本效益分析
Urol Oncol. 2023 Sep;41(9):391.e1-391.e4. doi: 10.1016/j.urolonc.2023.04.005. Epub 2023 Apr 29.
6
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.对弗朗切斯科·蒙托西、朱塞佩·罗西耶洛和乔治·甘达利亚致编辑的信的回复，信的主题为：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等人。欧洲泌尿外科协会极高危非肌层浸润性膀胱癌患者接受卡介苗或早期根治性膀胱切除术的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。
Eur Urol Oncol. 2024 Apr;7(2):301. doi: 10.1016/j.euo.2023.09.018. Epub 2023 Oct 6.
7
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.回复：吉西他滨和多西他赛序贯膀胱内灌注治疗初治的卡介苗耐药高危非肌层浸润性膀胱癌
Eur Urol. 2022 Dec;82(6):659. doi: 10.1016/j.eururo.2022.08.024. Epub 2022 Sep 8.
8
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.顺行膀胱内吉西他滨和多西他赛与卡介苗治疗高危非肌肉浸润性膀胱癌患者的比较。
JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849.
9
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.序贯吉西他滨联合多西他赛是卡介苗无反应性非肌层浸润性膀胱癌的标准二线膀胱内治疗方法：专家观点
Eur Urol Focus. 2022 Jul;8(4):1117-1120. doi: 10.1016/j.euf.2021.07.018. Epub 2021 Sep 27.
10
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Eur Urol Focus. 2022 Jul;8(4):1121-1123. doi: 10.1016/j.euf.2021.09.005. Epub 2021 Sep 17.